Drug intelligence / Profile preview

GF-1005

Development stage: Preclinical
Lead developer: GenFlow Biosciences
Modality: Cell Therapies, Gene Therapies
Administration: Intramuscular

Overview

GF-1005 is a gene therapy candidate developed by Genflow Biosciences in collaboration with Revatis SA and EXO Biologics for the treatment of sarcopenia (age-related muscle loss) and Werner Syndrome. The therapeutic approach involves the delivery of a proprietary centenarian variant of the SIRT6 gene (centSIRT6) into muscle-derived mesenchymal stem cells (mdMSCs) or myoblast progenitors. By restoring SIRT6 levels and mitochondrial health, GF-1005 aims to counteract age-related muscle mass and function loss. The program is currently in preclinical development and has received non-dilutive funding from the Walloon government to support its research and development milestones.

Other names: centSIRT6 gene therapycentSIRT-6 gene therapycentSIRT 6 gene therapy

Beyond the preview

Go deeper on GF-1005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GF-1005.

Explore the full profile